Topoisomerase genes were analyzed at both DNA and RNA levels in 25 cases of newly diagnosed childhood acute lymphoblastic leukemia (ALL). The results of molecular analysis were compared to risk group classification of children in order to identify molecular characteristics associated with response to therapy. At diagnosis, allelic imbalance at topoisomerase IIa (TOP2A) gene locus was found in 75% of informative cases whereas topoisomerase I and IIb gene loci are altered in none or only one case, respectively. By semiquantitative Polymerase chain reaction, we found a 2.5 to 8-fold TOP2A gene amplification in 72% of the children, which was correlated to gene overexpression in every case. These results show that TOP2A gene amplification is a frequent event in ALL at diagnosis. Interestingly, we also identified a small population of children that do not present TOP2A gene amplification or gene overexpression and who are significantly associated with very high risk classified patients showing glucocorticoid resistance. In conclusion, characterization of TOP2A gene status in childhood ALL at diagnosis provides useful complementary information for risk assessment.
Introduction
Acute lymphoblastic leukemia (ALL) represents the most common hematological malignancy encountered in children. As a result of chemotherapy and supportive care improvements, the long-term complete remission rate now reaches up to 80%. 1 This increase in long-term event-free survival can be attributed to the development of more effective risk-directed multidrug protocols, whose goal is to intensify the therapy for those patients with a high risk of relapse and to decrease the toxicity while maintaining high cure rates for those patients with a lower risk of relapse. 2 Current protocols include agents that have been shown to inhibit DNA topoisomerases and that are combined in the induction regimen with corticosteroids, vincristine and l-asparaginase in order to induce a complete remission during the first month of therapy. These agents are also used during the consolidation therapy, where they are associated with a variety of drugs including methotrexate, 6-mercaptopurine, 6-thioguanine, l-asparaginase, aracytine or cyclophosphamide, depending on protocols and risk assessment. 2, 3 DNA topoisomerases are essential nuclear enzymes that play a crucial role in the control of DNA topology. They are involved in the resolution of conformational constraints that occur during fundamental nuclear metabolic processes such as replication, transcription, recombination or chromosome segregation. 4 These enzymes act by promoting transient DNA breakage in order to allow strand-passage events and DNA relaxation to occur before rejoining the broken DNA ends. 5 Two types of DNA topoisomerases have been described. Type I enzymes, encoded in humans by the TOP1, TOP3A and TOP3B genes, [6] [7] [8] cleave only one strand of the DNA helix whereas type II enzymes, encoded by the human TOP2A and TOP2B genes, 9, 10 cleave both DNA strands. In mammalian cells, expression of the TOP2A isoform is closely linked to proliferation state, with maximal protein levels and enzymatic activity in late S and G2/M phases, whereas TOP2B is constitutively expressed at high levels even in quiescent cells. [11] [12] [13] Childhood ALL treatments include essentially type-IIspecific inhibitors such as anthracyclines (daunorubicin, idarubicin, doxorubicin/adriamycin) or epipodophyllotoxins (etoposide, teniposide). During the catalytic reaction of DNA topoisomerases, these drugs stabilize enzyme-DNA cleavable complexes, either by intercalating into the groove between DNA strands or by interfering with the DNA religation reaction of the enzyme. [14] [15] [16] Consequently, topoisomerase inhibitors lead to the accumulation of DNA strand breaks and ultimately to cell death. [17] [18] [19] The resistance of several leukemia cell lines to anthracyclines and epipodophyllotoxins has been associated with a decreased protein expression and/or activity of topoisomerase II enzymes. [20] [21] [22] [23] [24] [25] In addition, in some particular cell lines, topoisomerase II gene mutations have been identified and suggested to be responsible for the reduced drug sensitivity to DNA topoisomerase inhibitors. [26] [27] [28] [29] Conversely, more recent studies have shown that increasing the intracellular level of the enzyme by transfection of topoisomerase genes can restore the sensitivity of resistant cancer cell lines to DNA topoisomerase inhibitors. [30] [31] [32] [33] [34] On the other hand, anthracyclines are wellknown chemotherapeutic agents that can cause cardiotoxicity in clinical use. 35 In addition, epipodophyllotoxins, as well as other DNA topoisomerase II inhibitors, have been implicated in the occurrence of therapy-related acute myeloid leukemia and myelodysplastic syndromes. 36, 37 Regarding these data, trying to better adapt the use of DNA topoisomerase inhibitors to leukemia cells biological features could lead to a potential reduction of therapy-related cardiotoxic effects as well as secondary leukemias induced by these drugs. In this context, molecular characterization of the cellular target of these inhibitors could represent interesting first information. Therefore, we have analyzed topoisomerase genes at both DNA and RNA levels, in samples from 25 newly diagnosed children with ALL, using allelotyping and semi-quantitative fluorescent polymerase chain reaction (PCR) approaches. Results were compared to risk group classification of children at diagnosis in order to characterize topoisomerase gene status in different groups of patients.
Materials and methods

Patients
Twenty-five children (7 girls and 18 boys) referred for diagnosis of primary ALL at the Department of Pediatric Hematology and Oncology of the Hô pital de Hautepierre (Strasbourg, France) were included in the study. Their characteristics are summarized in Table 1 . The mean age at presentation was 6.3 years (range: 3 months to 14 years, only one case being diagnosed in the first 12 months of life). Leukemia (19 B-ALL and 6 T-ALL) was classified according to the European Group for Immunological Characterization of Leukemia (EGIL) criteria. 38 Children were included in very low, average or very high risk treatment groups of the European Organization for the Research and Treatment of Cancer (EORTC) protocols 58881 and 58951, according to criteria based on the age at diagnosis, white blood cell count at day 8 after glucocorticoid therapy, immunophenotype and cytogenetic analyses. 39 
Cytogenetic analysis
Chromosome analysis was performed according to the Rbanding method after short (24 or 48 h) culture of bone marrow cells without addition of mitogens.
Sample collection for molecular analysis
All samples were taken before induction therapy. Normal tissue was obtained from buccal swabs or fibroblasts cultures whereas ALL cells were recovered from bone marrow aspirates containing >70% leukemic blast cells (mean: 90%), as determined by May Grü nwald Giemsa staining. Oral swab cells were spun at 2500 g for 10 min and washed twice with phosphate buffered saline. Mononucleated cells were isolated from bone marrow samples by the standard Ficoll technique. Cell aliquots were stored at À801C until nucleic acid isolation.
Nucleic acid isolation from cytological samples
Genomic DNA was extracted with the classical phenolchloroform procedure and resuspended at 50 ng/ml final concentration. Total RNA was isolated from 10 7 cells with RNeasy kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. Reverse transcriptase (RT) reaction was performed in a total volume of 33 ml using random hexaprimers and 10 ml total RNA as template (First-Strand cDNA Synthesis Kit, Amersham Pharmacia Biotech, Uppsala, Sweden).
Microsatellite analysis
Two microsatellites surrounding each topoisomerase gene in close vicinity were analyzed in paired normal and tumoral DNA: D20S107 and D20S170 for TOP1 gene, D17S800 and D17S1814 for TOP2A gene, D3S1283 and D3S700 for TOP2B gene (see http://www.gdb.org and http://www.ncbi.nlm.nih. gov/genemap99 for microsatellite primers description). In total, 100 ng of genomic DNA was amplified by PCR in a total volume of 25 ml using 0.6 units of Taq polymerase and 4 pmol of both forward and Cy5-labelled reverse primers, as previously described. 40, 41 PCR was carried out in an Omnigen Hybaid Thermocycler (Hybaid Ltd, Ashford, UK) using the following protocol: initial denaturation of 7 min at 951C, 35 amplification cycles of 1 min at 951C, 1 min at 551C, and 1 min at 721C, followed by a final elongation of 5 min at 721C.
Semi-quantitative PCR analysis
TOP2A and TOP2B genes status were analyzed separately using glyceraldehyde-3-phosphate dehydrogenase (GAPDH ) gene co-amplification as an internal standard for quantification of gene amplification. A total of 100 ng of genomic DNA was used in a multiplex PCR amplification performed in a total volume of 25 ml using the following optimized primer amounts: 10 pmol of TOP2A and 1.2 pmol of GAPDH primers for TOP2A gene analysis, 1 pmol of TOP2B and 1 pmol of GAPDH primers for TOP2B gene analysis. PCR amplification cycles were performed as described above, except that three independent PCR reactions of 28, 31 and 35 cycles were done in parallel. This procedure allowed us to determine the condition for which, in each sample, topoisomerase and GAPDH genes amplifications are simultaneously in the exponential phase, which is the condition required for an accurate quantification of both genes amplification levels. Sequences of the primers used for genomic amplification are as follows: TOP2A Cy5-labelled forward primer (exon 11) 5 0 -GCCATTGGCTGTGGTATTG-3 0 and TOP2A reverse primer (exon 12) 5 0 -GAGAAGCTTCTCGAACATTGAG-3 0 were previously described 42 and lead to an amplified fragment of 656 bp on DNA, TOP2B Cy5-labelled forward primer (exon Table 1 Patients at diagnosis 
No. of patients (%)
Semi-quantitative RT-PCR analysis
TOP2A gene expression was analyzed using porphobilinogen deaminase (PBGD) gene as an internal standard for quantification. A 2.5 ml amount of the total volume of RT reaction performed as described above was used in three multiplex PCR reactions of 28, 31 and 35 amplification cycles. Experimental conditions were as mentioned for semiquantitative PCR analysis, except that 2.5 pmol of primers was used for both TOP2A and PBGD genes and that primers hybridization was performed at 601C. Primers used for TOP2A gene amplification are as described above, leading to an amplified product of 289 bp on cDNA. 42 Sequences of the primers used for PBGD gene co-amplification are as follows: Cy5-labelled forward primer (exon 1) 5
0 -CTGGTAACGG-CAATGCGGCT-3 0 and reverse primer (exon 7) 5 0 -GCA-GATGGCTCCGATGGTGA-3 0 (amplified product of 328 bp on cDNA).
PCR product analysis
Fluorescent PCR products were analyzed by denaturating polyacrylamide gel electrophoresis on an ALF (automated laser fluorescent) sequencer (Amersham Pharmacia Biotech, Uppsala, Sweden). Fluorescent signals were quantified using the ALFwin Fragment Analyser software package. Allelic imbalance at microsatellite markers, which is defined by the partial or complete loss of one of the two alleles or, alternatively, the amplification of one allele compared to the other, was quantified as previously described. 40, 41 Amplification levels of topoisomerase genes at both DNA and RNA levels are expressed as the ratio of bone marrow cells and paired normal tissue normalized values.
Results
Microsatellite topoisomerase genes analysis
As a first step in evaluating topoisomerase genes status in childhood ALL, TOP1, TOP2A and TOP2B genes allelotyping analysis was performed using two microsatellite markers surrounding each topoisomerase gene in close vicinity. The results are detailed in Table 2 for TOP2A gene and summarized in Table 3 for the three topoisomerase genes.
A total of 17 children were analyzed for TOP2A genomic rearrangements using D17S1814 and D17S800 microsatellite markers. Interestingly, regions associated with these loci appeared to be highly rearranged in ALL cells. When we compared the microsatellite allele ratio in paired bone marrow and buccal swab cells, allelic imbalance was indeed observed in 7 out of 14 informative heterozygous cases for D17S1814 TOP2A gene marker, and in 5 out of 12 informative cases for D17S800 (Table 2 ). In order to translate these data at the TOP2A gene locus level, we considered patients as Topoisomerase genes in childhood ALL E Guérin et al informative if they were heterozygous for both microsatellite markers or if at least one of these markers was rearranged. In this case, 9 out of 12 informative children (75%) showed TOP2A gene allelic imbalance, some children having both markers rearranged simultaneously (Table 3 ). This result contrasts with TOP1 and TOP2B genes allelotyping data. No alteration at the TOP1 gene locus and only one at the TOP2B gene locus were indeed observed in the 15 children that were also analyzed for these loci (Table 3) . From these data, we can conclude that among the three topoisomerase genes tested, TOP2A is clearly the most frequently altered in ALL cells. Therefore, we next focused on this gene in order to find out whether modifications observed at microsatellite sequence levels could be associated with an amplification or a deletion of TOP2A gene in leukemia cells.
Semi-quantitative PCR analysis of topoisomerase genes TOP2A gene amplification levels were evaluated by semiquantitative PCR performed on paired bone marrow and buccal samples. The housekeeping gene GAPDH was used as an internal co-amplified control, which allowed us to normalize TOP2A amplification levels between paired samples. In order to quantify both TOP2A and GAPDH genes in the exponential phase of amplification, several PCR reactions were performed in parallel with an increasing number of cycles. Figure 1 shows two representative examples of TOP2A gene quantification in ALL children with and without gene amplification.
TOP2A gene analysis was performed in the 25 children included in the study as well as in 10 control patients without ALL. In this control population, the highest ratio value (mean + 3 standard deviation) of TOP2A gene levels observed in test and control tissues was 1.8-fold (data not shown). Therefore, in our experimental conditions, a cut-off of more than 2.0-fold was considered as representative of TOP2A gene amplification. Using this threshold, results obtained in the 25 ALL children showed that 18 of them presented TOP2A gene amplification, whose value ranged between 2.5-and 8.0-fold (Table 2) . Among these TOP2A gene amplified patients, five presented a moderate gene amplification that was less than 3-fold, whereas TOP2A gene amplification ratio was over 3-fold in the 13 remaining cases. By contrast but in agreement with allelotyping data, TOP2B gene was never found amplified in the 14 children that we analyzed so far (Table 4) .
From these data, we can conclude that TOP2A gene amplification in ALL cells is a frequent event that is observed in 72% of the children at diagnosis, independently of leukemia Table 3 Topoisomerase genes allelotyping Patients for which at least one of both microsatellites presents an AI (ie AI/AI, AI/N or AI/H).
Figure 1
Semi-quantitative PCR analysis of TOP2A gene. Genomic DNA was extracted from paired bone marrow and buccal swab samples. TOP2A and GAPDH genes were co-amplified by multiplex PCR using fluorescent labelled primers. Several reactions were performed in parallel with an increasing number of cycles. Amplified fragments were analyzed by electrophoresis on a sequence analyzer. Fluorescence peak height of TOP2A amplified fragment (656 base pairs) is expressed relative to that of GAPDH fragment (104 bp). Panel a shows a representative example of TOP2A gene amplification in bone marrow cells compared to control cells. Panel b shows a representative sample without TOP2A gene amplification.
Topoisomerase genes in childhood ALL E Guérin et al cellular type (14 out of 19 B-ALL and 4 out of 6 T-ALL) ( Table  2 ). Having demonstrated that the TOP2A gene is amplified in ALL cells of most children, the next step was to find out whether this amplification was associated with gene overexpression at the RNA level.
Semi-quantitative RT-PCR analysis of TOP2A gene
Total RNA was extracted from bone marrow cells and control tissues. After reverse transcription, TOP2A and PBGD gene transcripts were co-amplified by multiplex PCR. As mentioned for semi-quantitative PCR analysis, several conditions of PCR amplification were used in parallel, in order to compare normalized TOP2A gene expression levels in leukemia cells and in control tissue. Figure 2 shows a typical profile of a patient with TOP2A gene overexpression in bone marrow cells. RT-PCR ratio values of TOP2A gene overexpression are indicated in Table 2 for the 14 children in which we could obtain RNA from biological samples.
Among the 14 analyzed children, 11 of them presented TOP2A gene amplification in leukemia cells at the DNA level. Interestingly, in every case, this gene amplification was associated with an overexpression of the gene at the RNA level. However, as shown in Table 2 , gene overexpression levels (3.0 -32.0-fold) appeared much more variable than DNA amplification levels. Finally, the three children in which the TOP2A gene was not amplified did not show any TOP2A gene overexpression.
Cytogenetic analysis
When TOP2A gene amplification results were compared to cytogenetic data (Table 5) , except in patient 8, no correlation was found between amplification of TOP2A gene located in 17q21-q22 and chromosome 17 duplication. As quantification of TOP2A gene amplification was performed after normalization with GAPDH gene located in 12p13, it was important to check that chromosome 12 was not deleted in ALL cells. Cytogenetic analyses showed us that it was the case for all children, except for patient 16, in which a del (12) (p11) is observed. However, in this patient, TOP2A gene overexpression at the RNA level (3.0-fold) was formally demonstrated using another reference gene, PBGD, located on band q23.3 of chromosome 11, for which no alteration in leukemia cells karyotype was found. Therefore, these cytogenetic data allowed us to validate the semi-quantitative evaluation of TOP2A gene amplification in all samples.
Comparison of TOP2A gene status and risk group classification
In our cohort, seven children were included in the very high risk (VHR) group of treatment, two of them (patients 1 and 11) because of the presence at diagnosis of a translocation t(9;22), four of them (patients 7,9,15 and 18) because of the persistence of blast cells in peripheral blood after 8 days of glucocorticoid therapy alone (see Table 5 ), and the last one (patient 17) because of the persistence of residual blast cells detectable in bone marrow by molecular analysis after 35 days of induction therapy. In our cohort, we first looked for a correlation between TOP2A gene status and glucocorticoid response, which can be evaluated at day 8 since at this time point the only systemic treatment that children have received is intravenous injection of glucocorticoids. If we exclude the two t(9;22) positive VHR cases since the presence of t (9;22) is an independent factor of high risk, we observed that three (patients 9, 15 and 18) out of the four children that do not respond to 8 days of glucocorticoid therapy do not present any TOP2A gene amplification, whereas the absence of TOP2A gene amplification is detected in only three (patients 3, 12 and 17) out of the 19 other patients that had a positive response at day 8 (P = 0.04 using Fisher exact test). Therefore, the absence of TOP2A gene amplification appeared to be significantly associated with patients resistant to glucocorticoids.
We next looked for a correlation between TOP2A gene status and VHR classification at the end of induction therapy (day 35), independently of the presence of t(9;22). Our results showed that four (patients 9, 15, 17 and 18) out of the five t(9;22) negative children that were VHR classified at day 35 do not present any TOP2A gene amplification whereas the absence of TOP2A gene amplification is detected in only two (patients 3 and 12) out of the 18 other average risk (AR) and very low risk (VLR) patients (P=0.008 using Fisher exact test).
Figure 2
Semi-quantitative RT-PCR analysis of TOP2A gene. Total RNA was extracted from paired bone marrow cells and control tissues. After reverse transcription, TOP2A and PBGD gene transcripts were co-amplified by multiplex PCR using an increasing number of cycles. Fluorescence peak height of TOP2A cDNA amplified fragment (289 bp) is expressed relative to that of PBGD cDNA fragment (328 bp). This figure shows a representative analysis of a sample with TOP2A gene overexpression in bone marrow cells. 
Altogether, our results show that TOP2A gene is amplified and overexpressed in most of the ALL children at diagnosis (72% of the cases), and that cases without TOP2A gene amplification are significantly associated with most of VHR patients showing resistance after 8 or 35 days of therapy.
Discussion
In recent years, only few studies have addressed the issue of topoisomerase genes molecular characterization in childhood ALL. Most studies have indeed been focused on the comparison of topoisomerase genes expression levels between specimens of newly diagnosed and relapsed ALL which were often unpaired. Moreover, expression levels were often indicated as percentages of the value found in a particular cell line chosen as a standard, hampering the exact quantification of gene expression level in blast cells. [43] [44] [45] [46] In two other studies performed on clinical samples of untreated childhood ALL, topoisomerase II expression level was determined with rather low-sensitive techniques such as immunocytochemistry or dot-blot hybridization, although the results were substantiated in some cases by semi-quantitative RT-PCR assays. 47, 48 Finally, none of these studies evaluated the precise status of topoisomerase genes at the DNA level. Therefore, the aim of our study was to analyze the status of topoisomerase genes at both the DNA and RNA levels, using highly sensitive semi-quantitative fluorescent PCR, in a population of 25 cases of newly diagnosed childhood ALL. We compared the results of molecular analysis to risk group classification of children in order to identify molecular characteristics associated with response to therapy, especially in the group of VHR children showing resistance to glucocorticoids.
In order to investigate topoisomerase genes status at the DNA level, we first performed an allelotype analysis using microsatellite markers surrounding TOP1, TOP2A and TOP2B genes in close vicinity. Allelotyping is a powerful method that discriminates both maternal and paternal alleles and which is therefore very informative to study precisely genomic rearrangements at a defined locus. In blast cells of ALL children, the TOP2A gene locus is more specifically altered than the two other topoisomerase genes. Allelic imbalance at the TOP2A gene locus is indeed found in 75% of informative cases, whereas no alteration at the TOP1 gene locus and only one at the TOP2B gene locus are observed. In order to further characterize TOP2A genomic rearrangements, we next evaluated gene amplification levels in leukemia cells by semi-quantitative PCR. Of the children 72% presented TOP2A gene amplification, which was well correlated with gene locus allelic imbalance in informative patients. Only patient 15 presented allelic imbalance restricted to one of the two studied TOP2A microsatellite markers but without concomitant gene amplification. For this patient, a deletion of TOP2A gene cannot be excluded. Conversely, patient 25 presented TOP2A gene amplification which was not correlated with D17S1814 and/or D17S800 markers allelic imbalance. For this patient, the extent of TOP2A gene amplified region could be more restricted without affecting those two markers. With the evolution of the human genome project, closer loci could be identified in order to precise the status of TOP2A gene in this patient. Altogether, these results show that molecular analysis of TOP2A gene at the DNA level represents a reliable and sensitive molecular test that can be easily and rapidly performed at the first day of diagnosis and which is positive in more than 70% of ALL children.
In ALL cells, except for patient 8, amplification of the TOP2A gene, located in 17q21-q22, is observed indepen- Table 5 Cytogenetic data and white blood cell count at days 0 and 8 Topoisomerase genes in childhood ALL E Guérin et al dently of any chromosome 17 duplication. This result suggests the presence of a defined and limited amplicon localized at the level of the TOP2A gene, which might not be evidenced by conventional cytogenetic analysis. Amplification of the TOP2A genomic region was already reported in other malignancies, such as in roughly 25% of breast cancers, in which the TOP2A gene was always simultaneously co-amplified with the ERBB2 gene, although fiber fluorescent in situ hybridization demonstrated that both genes are localized on two independent amplicons. 49, 50 In ALL cells, in the 16 TOP2A amplified cases that were also analyzed for ERBB2 gene status, co-amplification of both genes was similarly observed in 13 cases, but isolated TOP2A gene amplification could also be observed in three cases (data not shown). Further studies with additional genomic markers are now required to delineate more precisely the extent of TOP2A gene amplicon in ALL cells.
In the 14 cases in which we could perform TOP2A gene analysis at the RNA level, we found a total correlation between gene overexpression and gene amplification. The 11 children in which TOP2A gene was amplified presented simultaneous gene overexpression and the three remaining cases in which TOP2A gene was not amplified were similarly not associated with any gene overexpression. These results show that analysis of TOP2A gene at the RNA level is as sensitive as DNA analysis. However, as reported in previous studies, 43, 45 we also found large interpatient variations in TOP2A gene expression levels, suggesting that in addition to a simple increase in TOP2A gene copy number, transcriptional and/or post-transcriptional regulation mechanisms might also be implicated in the increased expression of TOP2A gene in ALL cells.
We also evaluated TOP2A gene status at the DNA level in 16 samples of acute myelogenous leukemias (AML). In contrast to ALL samples, none of these AML presented TOP2A gene amplification (data not shown). This result confirms previous reports tending to show lower TOP2A gene expression levels in primary AML compared to human Tlymphoblastoid cell lines as controls. 43, 46 In our cohort of ALL patients, we also identified a small population of children, around 20%, in which TOP2A gene is not amplified or overexpressed and which, remarkably, tends to correspond to most of the VHR patients exhibiting glucocorticoid resistance. This information, which can be rapidly and easily available at the day of diagnosis through the molecular analysis of TOP2A gene, represents a complementary and independent factor that can be useful for a better and faster characterization of VHR patients. From a mechanistic point of view, this link observed between the absence of TOP2A gene amplification and the in vivo resistance to glucocorticoids in VHR patients could be explained, at least in part, by the known propensity of TOP2A to trigger cell death apoptosis when overexpressed in mammalian cells. 51 Therefore, we speculate that potential low levels of TOP2A could reduce the pro-apoptotic potential of leukemia cells and hence reduce the sensitivity of these cells to glucocorticoids, which are known to induce apoptosis. 52 As a consequence, blast cells would persist in peripheral blood, leading the children to be classified in the VHR group. In order to confirm this hypothesis, additional investigations at the protein level are now required, first to verify that TOP2A protein levels actually correlate with TOP2A gene status and RNA expression levels. In addition, functional studies would be useful to directly assess the level of resistance of those TOP2A non-amplified ALL cells and to evaluate a possible generalized inability of these cells to undergo apoptosis.
In conclusion, our results, in a first series of 25 cases, show that the absence of TOP2A gene amplification is a complementary and independent factor that can be easily and rapidly determined at the first day of diagnosis using a reliable molecular test and which is associated with a high probability for the children to be resistant mainly to glucocorticoids and to be classified in the VHR group. These results now need to be extended and confirmed in a larger population using more sensitive techniques like real-time PCR quantification. In addition, longer follow-up of children might indicate if TOP2A gene status could be considered as a prognostic factor of the patient's response to the global chemotherapy and/or of the patient's relapse.
